Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...

Chinese scientists have classified the nasopharyngeal carcinoma into three proteomic subtypes for the first time, according to a new study published in the journal Nature Cancer. The breakthrough ...

Adjuvant therapy with camrelizumab significantly improved 3-year event-free survival in patients with locoregionally advanced nasopharyngeal carcinoma compared with observation, according to findings ...

Researchers from the University of Hong Kong have discovered that the Epstein-Barr virus (EBV), a common human virus closely linked to nasopharyngeal carcinoma (NPC), can change the 3D structure of ...

Ma Jun, vice-president of the cancer center and an academician of the Chinese Academy of Sciences, said radiation therapy is ...

In a phase 3 trial, toripalimab-based chemotherapy with radiotherapy without concurrent cisplatin achieved noninferior 3-year failure-free survival compared with standard therapy in patients with ...

As a first-line therapy, the risk of disease progression or death was reduced by 55% in the pempulimab-kcqx group vs the placebo group. The Food and Drug Administration (FDA) has approved ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

Molecular profiling of over 1,000 nasopharyngeal cancer (NPC) patients’ tumours reveals distinct differences in tumour microenvironment of locoregionally advanced NPC, supporting the use of ...

Penpulimab-kcqx is approved for first-line treatment of recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine. As a single agent, penpulimab-kcqx is ...